title: Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
abstract: Recent clinical studies in multiple sclerosis (MS) provide new data on the treatment of clinically isolated syndromes, on secondary progression, on direct comparison of immunomodulatory treatments and on dosing issues. All these studies have important implications for the optimized care of MS patients. The multiple sclerosis therapy consensus group (MSTCG) critically evaluated the available data and provides recommendations for the application of immunoprophylactic therapies. Initiation of treatment after the first relapse may be indicated if there is clear evidence on MRI for subclinical dissemination of disease. Recent trials show that the efficacy of interferon beta treatment is more likely if patients in the secondary progressive phase of the disease still have superimposed bouts or other indicators of inflammatory disease activity than without having them. There are now data available, which suggest a possible dose-effect relation for recombinant beta-interferons. These studies have to be interpreted with caution, as some potentially important issues in the design of these studies (e. g. maintenance of blinding in the clinical part of the study) were not adequately addressed. A meta-analysis of selected interferon trials has been published challenging the value of recombinant IFN beta in MS. The pitfalls of that report are discussed in the present review as are other issues relevant to treatment including the new definition of MS, the problem of treatment failure and the impact of cost-effectiveness analyses. The MSTCG panel recommends that the new diagnostic criteria proposed by McDonald et al. should be applied if immunoprophylactic treatment is being considered. The use of standardized clinical documentation is now generally proposed to facilitate the systematic evaluation of individual patients over time and to allow retrospective evaluations in different patient cohorts. This in turn may help in formulating recommendations for the application of innovative products to patients and to health care providers. Moreover, in long-term treated patients, secondary treatment failure should be identified by pre-planned follow-up examinations, and other treatment options should then be considered.
authors.affiliation: Dept. of Neurology, Josef-Schneider-Str. 11, 97080, Würzburg, Germany. p.rieckmann@mail.uni-wuerzburg.de
authors.forename: P
authors.initials: P
authors.lastname: Rieckmann
authors.forename: K V
authors.initials: KV
authors.lastname: Toyka
authors.forename: C
authors.initials: C
authors.lastname: Bassetti
authors.forename: K
authors.initials: K
authors.lastname: Beer
authors.forename: S
authors.initials: S
authors.lastname: Beer
authors.forename: U
authors.initials: U
authors.lastname: Buettner
authors.forename: M
authors.initials: M
authors.lastname: Chofflon
authors.forename: M
authors.initials: M
authors.lastname: Götschi-Fuchs
authors.forename: K
authors.initials: K
authors.lastname: Hess
authors.forename: L
authors.initials: L
authors.lastname: Kappos
authors.forename: J
authors.initials: J
authors.lastname: Kesselring
authors.forename: N
authors.initials: N
authors.lastname: Goebels
authors.forename: H-P
authors.initials: HP
authors.lastname: Ludin
authors.forename: H
authors.initials: H
authors.lastname: Mattle
authors.forename: M
authors.initials: M
authors.lastname: Schluep
authors.forename: C
authors.initials: C
authors.lastname: Vaney
authors.forename: U
authors.initials: U
authors.lastname: Baumhackl
authors.forename: T
authors.initials: T
authors.lastname: Berger
authors.forename: F
authors.initials: F
authors.lastname: Deisenhammer
authors.forename: F
authors.initials: F
authors.lastname: Fazekas
authors.forename: M
authors.initials: M
authors.lastname: Freimüller
authors.forename: H
authors.initials: H
authors.lastname: Kollegger
authors.forename: W
authors.initials: W
authors.lastname: Kristoferitsch
authors.forename: H
authors.initials: H
authors.lastname: Lassmann
authors.forename: H
authors.initials: H
authors.lastname: Markut
authors.forename: S
authors.initials: S
authors.lastname: Strasser-Fuchs
authors.forename: K
authors.initials: K
authors.lastname: Vass
authors.forename: H
authors.initials: H
authors.lastname: Altenkirch
authors.forename: S
authors.initials: S
authors.lastname: Bamborschke
authors.forename: K
authors.initials: K
authors.lastname: Baum
authors.forename: R
authors.initials: R
authors.lastname: Benecke
authors.forename: W
authors.initials: W
authors.lastname: Brück
authors.forename: D
authors.initials: D
authors.lastname: Dommasch
authors.forename: W G
authors.initials: WG
authors.lastname: Elias
authors.forename: A
authors.initials: A
authors.lastname: Gass
authors.forename: W
authors.initials: W
authors.lastname: Gehlen
authors.forename: J
authors.initials: J
authors.lastname: Haas
authors.forename: G
authors.initials: G
authors.lastname: Haferkamp
authors.forename: F
authors.initials: F
authors.lastname: Hanefeld
authors.forename: H-P
authors.initials: HP
authors.lastname: Hartung
authors.forename: C
authors.initials: C
authors.lastname: Heesen
authors.forename: F
authors.initials: F
authors.lastname: Heidenreich
authors.forename: R
authors.initials: R
authors.lastname: Heitmann
authors.forename: B
authors.initials: B
authors.lastname: Hemmer
authors.forename: T
authors.initials: T
authors.lastname: Hense
authors.forename: R
authors.initials: R
authors.lastname: Hohlfeld
authors.forename: R W C
authors.initials: RW
authors.lastname: Janzen
authors.forename: G
authors.initials: G
authors.lastname: Japp
authors.forename: S
authors.initials: S
authors.lastname: Jung
authors.forename: E
authors.initials: E
authors.lastname: Jügelt
authors.forename: J
authors.initials: J
authors.lastname: Koehler
authors.forename: W
authors.initials: W
authors.lastname: Kölmel
authors.forename: N
authors.initials: N
authors.lastname: König
authors.forename: K
authors.initials: K
authors.lastname: Lowitzsch
authors.forename: U
authors.initials: U
authors.lastname: Manegold
authors.forename: A
authors.initials: A
authors.lastname: Melms
authors.forename: J
authors.initials: J
authors.lastname: Mertin
authors.forename: P
authors.initials: P
authors.lastname: Oschmann
authors.forename: H-F
authors.initials: HF
authors.lastname: Petereit
authors.forename: M
authors.initials: M
authors.lastname: Pette
authors.forename: D
authors.initials: D
authors.lastname: Pöhlau
authors.forename: D
authors.initials: D
authors.lastname: Pohl
authors.forename: S
authors.initials: S
authors.lastname: Poser
authors.forename: M
authors.initials: M
authors.lastname: Sailer
authors.forename: S
authors.initials: S
authors.lastname: Schmidt
authors.forename: G
authors.initials: G
authors.lastname: Schock
authors.forename: M
authors.initials: M
authors.lastname: Schulz
authors.forename: S
authors.initials: S
authors.lastname: Schwarz
authors.forename: D
authors.initials: D
authors.lastname: Seidel
authors.forename: N
authors.initials: N
authors.lastname: Sommer
authors.forename: M
authors.initials: M
authors.lastname: Stangel
authors.forename: E
authors.initials: E
authors.lastname: Stark
authors.forename: A
authors.initials: A
authors.lastname: Steinbrecher
authors.forename: H
authors.initials: H
authors.lastname: Tumani
authors.forename: R
authors.initials: R
authors.lastname: Voltz
authors.forename: F
authors.initials: F
authors.lastname: Weber
authors.forename: W
authors.initials: W
authors.lastname: Weinrich
authors.forename: R
authors.initials: R
authors.lastname: Weissert
authors.forename: H
authors.initials: H
authors.lastname: Wiendl
authors.forename: H
authors.initials: H
authors.lastname: Wiethölter
authors.forename: U
authors.initials: U
authors.lastname: Wildemann
authors.forename: U K
authors.initials: UK
authors.lastname: Zettl
authors.forename: F
authors.initials: F
authors.lastname: Zipp
authors.forename: R
authors.initials: R
authors.lastname: Zschenderlein
authors.forename: G
authors.initials: G
authors.lastname: Izquierdo
authors.forename: A
authors.initials: A
authors.lastname: Kirjazovas
authors.forename: L
authors.initials: L
authors.lastname: Packauskas
authors.forename: D
authors.initials: D
authors.lastname: Miller
authors.forename: B
authors.initials: B
authors.lastname: Koncan Vracko
authors.forename: A
authors.initials: A
authors.lastname: Millers
authors.forename: A
authors.initials: A
authors.lastname: Orologas
authors.forename: M
authors.initials: M
authors.lastname: Panellus
authors.forename: C J M
authors.initials: CJ
authors.lastname: Sindic
authors.forename: M
authors.initials: M
authors.lastname: Bratic
authors.forename: A
authors.initials: A
authors.lastname: Svraka
authors.forename: N R
authors.initials: NR
authors.lastname: Vella
authors.forename: Z
authors.initials: Z
authors.lastname: Stelmasiak
authors.forename: K
authors.initials: K
authors.lastname: Selmaj
authors.forename: H
authors.initials: H
authors.lastname: Bartosik-Psujik
authors.forename: K
authors.initials: K
authors.lastname: Mitosek-Szewczyk
authors.forename: E
authors.initials: E
authors.lastname: Belniak
authors.forename: A
authors.initials: A
authors.lastname: Mochecka
authors.forename: A
authors.initials: A
authors.lastname: Bayas
authors.forename: A
authors.initials: A
authors.lastname: Chan
authors.forename: P
authors.initials: P
authors.lastname: Flachenecker
authors.forename: R
authors.initials: R
authors.lastname: Gold
authors.forename: B
authors.initials: B
authors.lastname: Kallmann
authors.forename: V
authors.initials: V
authors.lastname: Leussink
authors.forename: M
authors.initials: M
authors.lastname: Mäurer
authors.forename: K
authors.initials: K
authors.lastname: Ruprecht
authors.forename: G
authors.initials: G
authors.lastname: Stoll
authors.forename: F X
authors.initials: FX
authors.lastname: Weilbach
mesh_terms: D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000628:therapy*; D020528:Multiple Sclerosis, Chronic Progressive / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D016899:Interferon-beta